Logo Image
|Articles|December 1, 2007

Pharmaceutical Executive

  • Pharmaceutical Executive-12-01-2007
  • Volume 0
  • Issue 0

The List

It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings-and magazines make up their lists of hits and has-beens.

It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings—and magazines make up their lists of hits and has-beens. Here, at Pharm Exec, as we considered such weighty matters as which company's hot, which CEO's in the hot seat, and which ones are yesterday's news, we had to acknowledge the silliness of it all to an industry that makes lifesaving drugs and billion-dollar profits. Honest! Now let's dish.

Articles in this issue

almost 19 years ago

Financing the Future of Pharma

almost 19 years ago

Special Delivery: A Guide to the New Technologies

almost 19 years ago

Inviting Innovation

almost 19 years ago

Reach for the Radio

almost 19 years ago

The Pharm Exec Pipeline Report 2007

almost 19 years ago

Rethinking Vaccines: Q&A with Jane Quinn, GlaxoSmithKline

almost 19 years ago

Getting Personal

almost 19 years ago

What Moratorium?

almost 19 years ago

R&D Innovation: Climbing Out

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more